| Revenue growth | 8% Y-o-Y |
|---|---|
| Margins | EBITDA margin at 2.30% (+159 BPS Y-o-Y); gelatine capsules delivering healthy margins. |
| Demand visibility | Firm demand in capsules; erratic US HPMC environment. |
| Management confidence | Confident in sustained profitability for capsules; improved visibility for Q2FY27. |
Growth
Revenue grew 8% Y-o-Y to ₹48.71 Cr; PAT stood at a loss of ₹5.74 Cr. EBITDA rose 251% Y-o-Y.
Outlook
Converting two HPMC lines to gelatine; expecting first backward-integrated prednisolone batch by September 2026. PLI incentive of ~₹67 Cr over 6 years.
Risks
US HPMC demand remains erratic; geopolitical uncertainty and currency fluctuations impacting African export volumes via merchant exporters.
Last quarter's promises, checked
Delivered
- Guided Q4FY26 API sales start → Delivered Q4FY26 commencement (= BEAT)
- Guided HPMC line ready for qualification → Delivered ready for double zero (= BEAT)
Partly delivered
- Guided WHO GMP audit Q2FY27 → Delivered application initiated/audit expected (= PARTIAL)
- Guided Prednisolone commercial scale-up Q2/Q3 → Delivered synthesis at gram-scale (= PARTIAL)
Missed
- Guided FY27 HPMC revenue ₹20 Cr → Delivered Q1FY27 erratic demand (= MISS)
- Guided FY27 API revenue ₹70 Cr → Delivered Q1FY27 mixed picture/lower run-rate (= MISS)
Investor Presentation filed with BSE, NSE: NATCAPSUQ. Summary written with AI assistance from the document.
Natural Capsules Ltd: key numbers
- Share price
- ₹126.19
- Market cap
- ₹131.4 Cr
- Revenue (annual)
- ₹187.2 Cr
- Net profit (annual)
- ₹-24.66 Cr
- P/E (TTM)
- -8.3×Sector 49.0×
- Promoter holding
- 50.92%+0.00% QoQ
- FII holding
- 0.08%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Natural Capsules Ltd
All →Natural Capsules Earnings Call Transcript: Key Takeaways
Q2 revenue of ₹51.15 Cr (+12% YoY) and a narrower loss, but US capsule demand is absent, HPMC guidance is dropped, and FY27 API revenue guidance is cut to ₹12-15 Cr.
Natural Capsules Investor Presentation: Key Takeaways
Q2FY27 revenue ₹51.15 Cr (+12% YoY), EBITDA ₹3.01 Cr (5.88% margin), still PAT loss ₹4.22 Cr. Strategy: API scale-up, regulatory filings, CMO expansion.
Natural Capsules Results Update
Natural Capsules issued a press release on its Q2 and H1 FY27 results, citing volume growth and API restructuring. Management expects EBITDA to hold steady.
Natural Capsules Results Correction
Natural Capsules Ltd filed a corrigendum fixing a decimal error in six-month segment revenue (Capsules ₹9,050.16 Lakhs, API ₹936.31 Lakhs, total ₹9,986.47 Lakhs). The correction does not change reported results.
Natural Capsules Preferential Issue
Natural Capsules allotted 1,12,500 equity shares to a single investor at Rs.178 each on a preferential basis. The allotment is worth about Rs.2.00 Crore.
- Value
- ₹2.00 Cr
Natural Capsules Legal & Regulatory
Natural Capsules was fined ₹10,000 each by NSE and BSE for short board-meeting notice. The company has paid the fines and cited a late valuation report.
- Value
- ₹0.00 Cr